Pfizer (NYSE:PFE) Announces Earnings Results

Pfizer (NYSE:PFE) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09, FiscalAI reports. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $0.78 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.

Pfizer Stock Performance

Pfizer stock traded up $0.42 during trading hours on Tuesday, hitting $25.45. The company had a trading volume of 19,930,068 shares, compared to its average volume of 42,084,379. The firm has a 50-day moving average of $25.03 and a 200 day moving average of $26.16. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market cap of $145.04 billion, a PE ratio of 19.41 and a beta of 0.34. Pfizer has a one year low of $23.58 and a one year high of $28.75.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

Large investors have recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in Pfizer in the 2nd quarter valued at $32,000. IFC & Insurance Marketing Inc. bought a new position in Pfizer during the 4th quarter worth $34,000. Birchwood Financial Partners Inc. acquired a new position in shares of Pfizer in the fourth quarter valued at about $38,000. WFA of San Diego LLC bought a new position in Pfizer during the second quarter worth about $40,000. Finally, Atlas Capital Advisors Inc. bought a new position in Pfizer during the fourth quarter worth about $41,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, Morgan Stanley raised their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Quarterly results exceeded expectations: Pfizer reported adjusted earnings of $0.77 per share, above the $0.68 consensus estimate, while revenue reached $15.03 billion versus expectations of $14.40 billion. Revenue increased 2.6% year over year. Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
• Positive Sentiment: Non-COVID products are supporting growth: Strong demand for Eliquis, along with oncology and other launched or acquired products, helped offset weaker COVID-19 vaccine and treatment sales. This suggests Pfizer’s effort to diversify beyond pandemic-related revenue is gaining traction. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Full-year revenue outlook improved: Pfizer raised its 2026 revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, increasing the midpoint by $500 million. The company reaffirmed adjusted EPS guidance of $2.80-$3.00. Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
• Neutral Sentiment: Guidance remains broadly in line with forecasts: The EPS outlook is near the $2.97 analyst consensus, and the revenue range encompasses the approximately $61.7 billion consensus estimate. Pfizer said the Innovent Biologics transaction will reduce adjusted EPS by roughly $0.10.
• Negative Sentiment: Legacy headwinds remain: Pfizer swung to a quarterly loss on a reported basis, and second-quarter EPS was slightly below the year-ago $0.78. Continued declines in COVID-19 products and the relatively modest guidance increase limited the market’s enthusiasm. Pfizer Post Loss on Higher Revenue

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.